10 results on '"L. Heraudet"'
Number of results to display per page
Search Results
2. 1314P Preliminary results of sequential combination of immunotherapy followed by chemotherapy in advanced non-small cell lung cancer
- Author
-
C. Domblides, Charlotte Vergnenegre, Amaury Daste, Remi Veillon, H. Lepetit, L. Heraudet, M. Zysman, Alain Ravaud, and T. Delon
- Subjects
Oncology ,medicine.medical_specialty ,Chemotherapy ,business.industry ,medicine.medical_treatment ,Sequential combination ,Hematology ,Immunotherapy ,medicine.disease ,Internal medicine ,medicine ,Non small cell ,Lung cancer ,business - Published
- 2021
3. The head and neck lung immune prognostic index (HN-LIPI): A prognostic score for immune checkpoint inhibitors (ICI) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients
- Author
-
Solange Peters, Jaume Grau, Maria Teresa Plana, A. Garcia Castano, Caroline Even, Valerie Cristina, Khalil Saleh, B. Cirauqui Cirauqui, Neus Baste-Rotllan, Edouard Auclin, Amaury Daste, L. Heraudet, Miren Taberna, Benjamin Besse, Sébastien Salas, Laura Mezquita, Virginia Arrazubi, R.G. Herrera Gomez, and R. Mesia Nin
- Subjects
0301 basic medicine ,education.field_of_study ,medicine.medical_specialty ,business.industry ,Immune checkpoint inhibitors ,Population ,Hematology ,Prognostic score ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Risk groups ,Oncology ,Median follow-up ,030220 oncology & carcinogenesis ,Family medicine ,Medicine ,Basal cell ,education ,Head and neck ,business ,Objective response - Abstract
Background LIPI, based on derived NLR (neutrophils/(leucocytes-neutrophils)) and lactate dehydrogenase (LDH) level, has been correlated to ICI outcomes in advanced non small cell lung cancer. We evaluated if HN-LIPI could offer the same role in R/M SCCHN. Methods This is a multicentric (9 European centers) retrospective study including R/M SCCHN patients (pts) treated with ICI from September 2014 to May 2019 and a control cohort (N = 83) only treated with chemotherapy. Baseline biological and clinicaldata were collected from medical records. According to dNLR>3 and LDH > upper limit of normal, HN-LIPI defines 3 groups (Good: 0 factor; Intermediate: 1 factor; Poor: 2 factors).The primary endpoint was overall survival (OS), and secondary endpoints was progression free survival (PFS). Results We included 273 pts (84% male, 84% smokers and 87% with PS ≤ 1, median age 59 years). Primary tumor locations were: oropharynx (37%), oral cavity (23%) and hypopharynx (17%). p16by immunohistochemistry was positive in 33% oropharynx pts. ICI were administered in 53% of patients as monotherapy and in 47% in combination. The median number of prior lines was 2 (1-7) with 65% of pts receiving ≥2. Median follow up of 13.2 months (mo).The median (m) PFS and OS were 2.84 mo [2.53-3.52] and 11.8mo [9.4-15.8]. dNLR >3 was associated to poor OS(HR 1.6, 95%CI: 1.1-2.3) but not with PFS (p = 0.11). LDH was not associated with endpoints. Median OS for good, intermediate and poor LIPI groups were: 15.9mo, 8.9mo and 6.2mo, respectively (p=.03). In univariate analysis, Intermediate and Poor risk groups were associated with OS (HR:1.5 95%CI:1.1-2.2 and HR:2 95%CI:1.0-4. respectively ). There was trend to better objective response rate in the good risk group compared with intermediate and poor (36%, 22% and 18%, p = 0.09). Conclusions Baseline HN-LIPI is associated with worse OS for ICI in R/M SCCHN but not with PFS. Control cohort results and multivariate models will be further presented at the congress, which would elucidate the prognostic and/or predictive impact in R/M SCCHN population. Legal entity responsible for the study Neus Baste. Funding Has not received any funding. Disclosure V. Cristina: Advisory / Consultancy: Merck-Serono; Advisory / Consultancy: Ely Lilly; Advisory / Consultancy: Servier; Advisory / Consultancy: Celgene; Travel / Accommodation / Expenses: Bayer; Travel / Accommodation / Expenses: Merck-Serono. A. Garcia Castano: Advisory / Consultancy: Roche; Advisory / Consultancy: Novartis; Advisory / Consultancy: MSD; Advisory / Consultancy: BMS; Advisory / Consultancy: Pierre Fabre; Speaker Bureau / Expert testimony: Roche; Speaker Bureau / Expert testimony: Novartis; Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony: BMS; Speaker Bureau / Expert testimony: Pierre Fabre. R. Mesia Nin: Advisory / Consultancy: Merck; Advisory / Consultancy: BMS; Advisory / Consultancy: MSD; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Roche; Advisory / Consultancy: Nanobiotix; Speaker Bureau / Expert testimony: Merck; Speaker Bureau / Expert testimony: BMS; Speaker Bureau / Expert testimony: MSD. M. Taberna: Non-remunerated activity/ies: Merck Serono; Non-remunerated activity/ies: AstraZeneca; Travel / Accommodation / Expenses: Merck Serono; Travel / Accommodation / Expenses: Nanobiotics; Travel / Accommodation / Expenses: AstraZeneca; Travel / Accommodation / Expenses: MSD; Travel / Accommodation / Expenses: Bristol-Myers. B. Besse: Travel / Accommodation / Expenses: AbbVie; Travel / Accommodation / Expenses: Amgen; Travel / Accommodation / Expenses: AstraZeneca; Travel / Accommodation / Expenses: Biogen; Travel / Accommodation / Expenses: Blueprint Medicine; Travel / Accommodation / Expenses: BMS; Travel / Accommodation / Expenses: Celgene; Travel / Accommodation / Expenses: Eli Lilly; Travel / Accommodation / Expenses: GSK; Travel / Accommodation / Expenses: Ignyta; Travel / Accommodation / Expenses: IPSEN; Travel / Accommodation / Expenses: MERCK; Travel / Accommodation / Expenses: KGaA; Travel / Accommodation / Expenses: MSD; Travel / Accommodation / Expenses: Nektar; Travel / Accommodation / Expenses: Onxeo; Travel / Accommodation / Expenses: Pfizer; Travel / Accommodation / Expenses: Pharma Mar; Travel / Accommodation / Expenses: SANOFI; Travel / Accommodation / Expenses: Spectrum pharmaceuticals; Travel / Accommodation / Expenses: Tiziana Pharma; Travel / Accommodation / Expenses: Takeda. N. Baste-Rotllan: Advisory / Consultancy, Travel / Accommodation / Expenses: Merck Serono; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy, Travel / Accommodation / Expenses: Nanobiotics; Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Travel / Accommodation / Expenses: MSD. All other authors have declared no conflicts of interest.
- Published
- 2019
4. Efficacité et tolérance de la radiothérapie stéréotaxique des lésions primitives et secondaires hépatiques au CHU de Bordeaux
- Author
-
M. Lafon, M. Bacci, L. Heraudet, S. Coulibaly, Véronique Vendrely, M. Martin, R. Trouette, and C. Dupin
- Subjects
Oncology ,Radiology, Nuclear Medicine and imaging - Abstract
Objectif de l’etude La radiotherapie stereotaxique se developpe pour les lesions primitives (carcinome hepatocellulaire) ou secondaires (metastase) du foie. Elle est proposee en cas de contre-indication a la chirurgie ou a la radiofrequence et utilisee dans notre centre depuis 2013. Notre objectif etait d’evaluer la tolerance et le controle local hepatique apres radiotherapie stereotaxique chez les patients pris en charge dans notre institution. Materiel et methode De janvier 2013 a octobre 2017, 50 patients ont ete traites par irradiation stereotaxique pour 54 lesions (28 metastases et 26 carcinomes hepatocellulaires) dans le centre hospitalier universitaire de Bordeaux. Le traitement a ete prepare par une scanographie de centrage apres pose de reperes fiduciels, compression abdominale (33,3 %) ou scanographie quadridimensionnelle (57,4 %), et realise sur accelerateur Elekta versa HD®. La dose totale etait de 45 Gy pour les carcinomes hepatocellulaires et 48 a 60 Gy pour les metastases en trois a quatre fractions. Les recidives ont ete considerees comme dans le volume en cas de progression dans le volume cible previsionnel, en bordure de volume en cas de progression a moins de 5 mm du volume cible previsionnel. Le controle local etait defini comme l’absence de recidive dans le volume ou en bordure. Les survies ont ete calculees en utilisant la methode de Kaplan–Meier. Resultats Une seule toxicite de grade IV a ete observee (ulcere gastrique) alors que 18,5 % des patients ont souffert d’une toxicite de grade I–II. Le suivi median etait de 14,8 mois [1,1–41,6]. Le volume median traite etait de 7,5 cm3 (0,1–286), avec une dose d’au plus 45 Gy pour 83 % des lesions. Huit tumeurs ont recidive dans le volume, avec une recidive metastatique diffuse intrahepatique ou a distance, une a recidive uniquement dans le volume et trois en bordure. Les probabilites de controle local etaient de 81 % et 67 % respectivement a 1 et 2 ans, celles de survie globale de 90 % et 56 % a 1 et 2 ans, sans difference significative entre les carcinomes hepatocellulaires et les metastases. La dose prescrite, le volume traite et la couverture du volume cible previsionnel n’avaient pas d’influence sur la recidive. Conclusion La radiotherapie stereotaxique hepatique a permis un taux de controle local a un an de 81 %. Les deux-tiers des recidives dans ou en bordure du volume etaient diffuses dans le foie ou a distance.
- Published
- 2018
5. Clinical and Biological Differences between Upper Tract Carcinoma and Bladder Urothelial Cancer, Including Implications for Clinical Practice.
- Author
-
Lefort F, Rhanine Y, Larroquette M, Domblides C, Heraudet L, Sionneau B, Lambert S, Lasserre M, Robert G, Ravaud A, and Gross-Goupil M
- Abstract
Upper tract urothelial carcinoma (UTUC) is a rare disease included, along with the much more frequent urothelial bladder cancer (BUC), in the family of urothelial carcinomas (UCs). However, while UTUCs and BUCs share several features, their epidemiological, clinical, pathological, and biological differences must be considered to establish an optimal therapeutic strategy. This review examines the clinical differences between UTUC and BUC, as well as the main results obtained by molecular screening of the two diseases. The findings of clinical trials, performed in peri-operative and metastatic settings and assessing systemic treatments in UC, are summarised. A comparison of the data obtained for UTUC and BUC suggests improved therapeutic approaches, both in regards to routine practice and future drug development.
- Published
- 2023
- Full Text
- View/download PDF
6. Therapeutic Management of Metastatic Clear Cell Renal Cell Carcinoma: A Revolution in Every Decade.
- Author
-
Larroquette M, Lefort F, Heraudet L, Bernhard JC, Ravaud A, Domblides C, and Gross-Goupil M
- Abstract
Clear cell renal cell carcinoma (RCC) oncogenesis is mainly driven by VHL gene inactivation, leading to overexpression of vascular endothelial growth factor (VEGF). The use of tyrosine-kinase inhibitors (TKIs) directed against VEGF and its receptor (VEGFR) revolutionised the management of metastatic renal cancer in the 2000s. The more recent development of next-generation TKIs such as cabozantinib or lenvatinib has made it possible to bypass some of the mechanisms of resistance to first-generation anti-VEGFR TKIs. During the decade 2010-2020, the development of immune checkpoint blockade (ICB) therapies revolutionised the management of many solid cancers, including RCC, in first- and subsequent-line settings. Dual ICB or ICB plus anti-VEGFR TKI combinations are now the standard of care for patients with advanced clear cell RCC. To optimise these combination therapies while preserving patient quality of life, escalation and de-escalation strategies are being evaluated in prospective randomised trials, based on patient selection according to their prognosis risk. Finally, new therapeutic approaches, such as targeting hypoxia-inducible factor (HIF) and the development of innovative treatments using antibody-drug conjugates (ADCs), CAR-T cells, or radiopharmaceuticals, are all potential candidates to improve further patient survival., Competing Interests: The authors declare no conflict of interest.
- Published
- 2022
- Full Text
- View/download PDF
7. VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome-negative B-precursor acute lymphoblastic leukaemia in first relapse.
- Author
-
Heraudet L, Galtier J, Favre S, Peyraud F, Cazaubiel T, Leroy H, Mottal N, Gros FX, Forcade E, Clément L, Dumas PY, Pigneux A, and Leguay T
- Subjects
- Acute Disease, Adult, Humans, Neoplasm Recurrence, Local drug therapy, Philadelphia Chromosome, Recurrence, Antibodies, Bispecific therapeutic use, Antineoplastic Agents therapeutic use, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Abstract
Adults with relapsed or refractory B-precursor acute lymphoblastic leukaemia (R/R BCP-ALL) have very poor outcome. Blinatumomab as single agent has shown activity in R/R BCP-ALL. We aimed to assess the activity of blinatumomab in concomitant association with intensive chemotherapy. Seventeen patients with R/R BCP-ALL were treated with combination of blinatumomab and VANDA (etoposide, cytarabine, mitoxantrone, dexamethasone and asparaginase) regimen. Complete remission (CR) was achieved in 14/17 patient (82%) and 11/17 (65%) were transplanted. One-year leukaemia-free survival was 58.8% for the whole cohort and 90.9% for transplanted patients. These preliminary data suggest that the VANDA-blinatumomab salvage regimen leads to a very high rate of CR and HSCT in suitable patients., (© 2022 British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
8. Effect of prior immunotherapy on the efficacy of chemotherapy in advanced non-small cell lung cancer: A retrospective study.
- Author
-
Heraudet L, Delon T, Veillon R, Vergnenègre C, Lepetit H, Daste A, Ravaud A, Zysman M, and Domblides C
- Subjects
- Bevacizumab therapeutic use, Humans, Immunotherapy, Paclitaxel therapeutic use, Retrospective Studies, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
- Abstract
Background: The effect of the sequential combination of chemotherapy and immune checkpoint inhibitors (ICIs) remains unclear. Here, we evaluated the efficacy of different chemotherapy regimens administered after ICIs in advanced non-small cell lung cancer (NSCLC), compared to the same regimens administered without previous ICIs., Methods: We retrospectively included all patients treated between 2015 and 2019 for an advanced NSCLC, receiving a salvage chemotherapy just after ICI (CAI group) comparing them to ICI naive patients (CWPI group) undergoing the same chemotherapy at Bordeaux University Hospital. The primary outcome was the time to treatment discontinuation (TTD), and secondary endpoints were overall survival (OS) and overall response rate (ORR)., Results: A total of 152 patients were included, with 34/23 (CAI/CWPI) receiving paclitaxel/bevacizumab (PB), 24/11 paclitaxel (P), 27/12 gemcitabine (G) and 6/15 pemetrexed (PE). Characteristics were comparable, except for CAI treated with PB (more patients with an ECOG PS ≤1 [p <0.001]). Median number of lines received was higher in CAI for all groups. There was no difference between CAI and CWPI for TTD, OS and ORR. However, PB was associated with a nonsignificant increase in OS in the CAI group (HR = 0.65; 95% CI: 0.38-1.2, p = 0.17]., Conclusion: Our data showed no difference in TTD, OS and ORR regardless of chemotherapy, but a trend towards an increased OS with PB when given after an ICI, while patients received chemotherapy later in the CAI group. This suggests that a sequential combination of ICI followed by chemotherapy could be an interesting strategy in advanced NSCLC for selected patients., (© 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
9. Adaptation of multidisciplinary meeting decisions in a medical oncology department during the COVID epidemic in a less affected region of France: a prospective analysis from Bordeaux University Hospital.
- Author
-
Heraudet L, Domblides C, Daste A, Gross-Goupil M, and Ravaud A
- Subjects
- Clinical Decision-Making, Cooperative Behavior, France epidemiology, Humans, Interdisciplinary Communication, Neoplasms mortality, Neoplasms pathology, COVID-19, Hospital Departments, Hospitals, University, Medical Oncology, Neoplasms therapy, Patient Care Planning, Patient Care Team
- Abstract
Competing Interests: Conflict of interest statement Luc Heraudet : nothing declared. Charlotte Domblides: advisory board participation: Astra-Zeneca ; accommodations and Travel support: Pierre Fabre, Astra Zeneca, BMS, MSD, Pfizer; Honoraria: Astra Zeneca, MSD. Amaury Daste: advisory board participation for Merck GA, BMS; accommodations and travel support by Merck GA, BMS, Astra Zeneca. Baptiste Sionneau: honoraria by BMS and Ipsen, accommodations and travel support by Pfizer. Marine Gross-Goupil: advisory board participation for Pfizer, Merck GA, Novartis, Ipsen, Roche, Astra Zeneca, MSD, accommodations and travel support by Pfizer, Merck GA, Novartis, Ipsen, Roche, Astra Zeneca, MSD, honoraria MSD, BMS ,Ipsen. Alain Ravaud : non financial support by Pfizer and Merck GA, advisory board participation for Pfizer, Merck GA, Novartis, Ipsen, Roche, Astra Zeneca, MSD, accommodations and travel support by Pfizer, Merck GA, BMS, Novartis, Ipsen, Roche, Astra Zeneca, MSD.
- Published
- 2020
- Full Text
- View/download PDF
10. Safety of sunitinib in patients with renal cell carcinoma following nephrectomy.
- Author
-
Heraudet L, Domblides C, Daste A, Lefort F, Bernhard JC, Ravaud A, and Gross-Goupil M
- Subjects
- Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Carcinoma, Renal Cell pathology, Chemotherapy, Adjuvant, Humans, Kidney Neoplasms pathology, Neoplasm Metastasis, Nephrectomy, Sunitinib adverse effects, Carcinoma, Renal Cell therapy, Kidney Neoplasms therapy, Sunitinib administration & dosage
- Abstract
Introduction: The safety profile characteristics of sunitinib were evaluated in patients who underwent nephrectomy for kidney cancer., Areas Covered: In this literature review, safety data were evaluated from phase III trials investigating sunitinib following nephrectomy, either in the more recent adjuvant setting after nephrectomy or in the metastatic setting, with a focus on new data from the CARMENA and SURTIME trials. In particular, the aim was to determine the specificity of toxicity in the adjuvant setting., Expert Opinion: In the adjuvant setting, even if the toxicity profile of sunitinib does not differ significantly from that in the metastatic setting, the importance of the dose intensity and, thus, exposure has been emphasized. Consequently, as described mainly in the metastatic setting, management of the adverse effects of sunitinib remains critical.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.